Skinvisible IncOTCQB:SKVI
- LAST PRICE0.6700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.6700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | SKVI |
|---|
Jul 11, 2024
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible, from 3:56PM ET on Thursday Jul 11, 2024 by Dow Jones
3:56PM ET on Thursday Jul 11, 2024 by Dow Jones
Jul 9, 2024
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations, from 9:04AM ET on Tuesday Jul 09, 2024 by Dow Jones
9:04AM ET on Tuesday Jul 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Skinvisible Inc | 3.0M | -2.6x | --- |
Shonghoya Intl Group Inc | 3.1M | -0.1x | --- |
Mint Wellness Corp | 37.0K | 0.0x | --- |
Thermic Science International Corp | 590.0 | 0.0x | --- |
Science To Consumers Inc | 30.0 | 0.0x | --- |
Axia International Group Inc | 20.0 | 0.0x | --- |
Company Information
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.
Contact Information
- Headquarters
- 6320 S SANDHILL ROAD, UNIT 9LAS VEGAS, NV, United States 89120
- Phone
- 702-433-7154
- Fax
- 702-433-7192
Executives
- Chief Executive Officer, Chief Financial Officer, Director
- Terry Howlett
- Vice President - Business Development
- Doreen Mcmorran
- Independent Director
- David St. James
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0M |
|---|---|
Revenue (TTM) | $20.0K |
Shares Outstanding | 4.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.18 |
EPS | $-0.26 |
Book Value | $-1.99 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | 152.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,428.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
